---
title: "CRYO CELL INTERNATIONAL 3Q FY2026: Revenue $7.82M, 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301438966.md"
description: "Cryo Cell International reported Q3 FY2026 revenue of $7.82M, flat year-over-year. Growth in recurring storage fees was offset by a decline in new specimen enrollments. Operational expansion continues with a new Durham facility, but planned clinic and biopharma initiatives are paused due to a license dispute with Duke pending arbitration."
datetime: "2026-10-09T20:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301438966.md)
  - [en](https://longbridge.com/en/news/301438966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301438966.md)
generator: "portal-rs"
---

# CRYO CELL INTERNATIONAL 3Q FY2026: Revenue $7.82M, 10-Q Summary

CRYO CELL INTERNATIONAL INC reported third-quarter fiscal 2026 revenue of $7.82M, essentially flat with $7.83M in the year-ago quarter, as modest growth in recurring storage fees was offset by fewer new specimen enrollments.

**Financial Highlights**

-   Revenue: $7.82M for 3Q FY2026, compared with $7.83M in the year-ago quarter; YoY change 0%.
-   Net income: (Not reported in Part I Items 1–2); omitted per instructions.
-   Diluted EPS: (Not reported in Part I Items 1–2); omitted per instructions.

**Business Highlights**

-   Total revenue roughly flat year-to-date at about $23.3M versus $23.7M prior-year, with recurring storage growth of roughly 3% offset by a 15–16% decline in new specimen processing.
-   Channel and product mix: recurring storage fees provided modest growth while product and public bank sales were volatile but added incremental revenue.
-   Operational capacity expanded with a 56,000 sq ft cold storage facility in Durham (ExtraVault) to support third-party biorepository and MSC lab services.
-   Planned clinic, biopharma manufacturing and Celle spinoff initiatives are paused due to a license dispute with Duke; related investments are on hold pending arbitration.
-   Company maintains cGMP/cGTP, AABB/FACT accreditations and reports 100% historical specimen viability on thaw along with its proprietary PrepaCyte®-CB processing claim.

Original SEC Filing: CRYO CELL INTERNATIONAL INC \[ CCEL \] - 10-Q - Oct. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CCEL.US](https://longbridge.com/en/quote/CCEL.US.md)

## Related News & Research

- [CRYO CELL INTERNATIONAL INC Q2 2026: Revenue $7.78M (Q2), $15.46M (6 months) — 10-Q Summary](https://longbridge.com/en/news/292814991.md)
- [CCEL: Revenue and net income declined, with expansion paused due to Duke arbitration and NYSE compliance risks](https://longbridge.com/en/news/292814054.md)
- [Salesforce (CRM) Is Turning the AI Threat into an Opportunity](https://longbridge.com/en/news/302207857.md)
- [Is the golden decade over for bank shares?](https://longbridge.com/en/news/302241452.md)
- [SK Hynix Launches About $1.5 Billion Financing Plan With Korea Trade Insurance and Four Banks](https://longbridge.com/en/news/302262829.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**